Related Experiment Video

Updated: May 15, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation

Elizabeth Rico-Bautista, Dieter A Wolf

    Chemistry & Biology
    |December 25, 2012
    PubMed

    Insights

    Researchers have developed novel small molecule inhibitors targeting the CRL1(SKP2) complex, which drives the degradation of the tumor suppressor p27. These inhibitors offer a new therapeutic strategy for various human cancers.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Drug Discovery

    Background:

    • The CRL1(SKP2) complex is crucial for the degradation of the tumor suppressor p27.
    • p27 degradation is implicated in the progression of numerous human cancers.
    • CRL1(SKP2) represents a validated therapeutic target in oncology.

    Discussion:

    • Wu and colleagues report the development of first-in-class small molecule inhibitors.
    • These inhibitors specifically target the CRL1(SKP2)-mediated degradation pathway of p27.
    • This research presents a novel approach to inhibiting a key cancer-driving mechanism.

    Key Insights:

    • Discovery of small molecules that inhibit CRL1(SKP2) activity.
    • Demonstration of a new therapeutic avenue for targeting p27 degradation in cancer.
    • Validation of CRL1(SKP2) as a druggable target for anti-cancer therapies.

    Outlook:

    • Potential for developing new cancer treatments.
    • Further investigation into the efficacy and safety of these inhibitors.
    • Exploration of CRL1(SKP2) inhibitors in combination therapies.

    More Related Videos

    A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

    A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

    Published on: April 3, 2026

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

    Published on: July 17, 2020

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Inhibition of CDK Activity02:34

    Inhibition of CDK Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    Negative Regulator Molecules01:23

    Negative Regulator Molecules

    Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...